{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T21:59:51Z","timestamp":1789250391843,"version":"build-2803163510"},"reference-count":40,"publisher":"King Faisal Specialist Hospital and Research Centre","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Saudi Medicine"],"published-print":{"date-parts":[[2005,3]]},"DOI":"10.5144\/0256-4947.2005.143","type":"journal-article","created":{"date-parts":[[2018,8,6]],"date-time":"2018-08-06T21:48:03Z","timestamp":1533592083000},"page":"143-149","source":"Crossref","is-referenced-by-count":24,"title":["Anthrax Vaccines"],"prefix":"10.5144","volume":"25","author":[{"given":"Miroslav","family":"Splino","sequence":"first","affiliation":[{"name":"Department of Epidemiology, Military Medical Academy, Hradec Kralove, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiri","family":"Patocka","sequence":"additional","affiliation":[{"name":"Department of Toxicology, Military Medical Academy, Hradec Kralove, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Prymula","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Military Medical Academy, Hradec Kralove, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Chlibek","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Military Medical Academy, Hradec Kralove, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3134","reference":[{"key":"e_1_3_1_2_2","first-page":"142","article-title":"Anthrax: an important agent of biological terrorism","volume":"55","author":"Merka V","year":"2002","journal-title":"Nederl Milit Geneesk T"},{"key":"e_1_3_1_3_2","volume-title":"Biological and Chemical Terrorism","author":"Prymula R","year":"2002"},{"key":"e_1_3_1_4_2","first-page":"85","article-title":"Prophylaxis against anthrax","volume":"45","author":"Splino M","year":"2002","journal-title":"Acta Medica"},{"key":"e_1_3_1_5_2","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.281.18.1735","article-title":"Anthrax as a biological weapon: medical and public health management","volume":"281","author":"Inglesby TV","year":"1999","journal-title":"JAMA"},{"key":"e_1_3_1_6_2","first-page":"335","article-title":"Anthrax: clinical features, pathogenesis, and potential biological warfare threat","volume":"20","author":"Friedlander AM","year":"2000","journal-title":"Curr Clin Top Infect Dis"},{"key":"e_1_3_1_7_2","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1001\/jama.1997.03550050080037","article-title":"Iraq\u2019s biological weapons. The past as future?","volume":"278","author":"Zilinskas RA","year":"1997","journal-title":"JAMA"},{"key":"e_1_3_1_8_2","first-page":"341","article-title":"Surveillance for adverse events associated with anthrax vaccination\u2013U.S. Department of Defence, 1998\u20132000","volume":"49","author":"CDC","year":"2000","journal-title":"MMWR"},{"key":"e_1_3_1_9_2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1749-6632.1980.tb18910.x","article-title":"Inhalation anthrax","volume":"353","author":"Brachman PS","year":"1980","journal-title":"Ann N Y Acad Sci"},{"key":"e_1_3_1_10_2","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1126\/science.7973702","article-title":"The Sverdlovsk anthrax outbreak of 1979","volume":"266","author":"Meselson M","year":"1994","journal-title":"Science"},{"key":"e_1_3_1_11_2","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1093\/infdis\/167.5.1239","article-title":"Postexposure prophylaxis against experimental inhalation anthrax","volume":"167","author":"Friedlander AM","year":"1993","journal-title":"J Infect Dis"},{"key":"e_1_3_1_12_2","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S1438-4221(00)80030-2","article-title":"Characterization of a plasmid region involved in Bacillus anthracis toxin production and pathogenesis","volume":"290","author":"Sirard JC","year":"2000","journal-title":"Int J Med Microbiol"},{"key":"e_1_3_1_13_2","first-page":"81","article-title":"Structure and function of anthrax toxin","volume":"271","author":"Lacy DB","year":"2002","journal-title":"Curr Top Microbiol Immunol"},{"key":"e_1_3_1_14_2","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0041-0101(01)00161-1","article-title":"Toxins of Bacillus anthracis","volume":"39","author":"Brossier F","year":"2001","journal-title":"Toxicon"},{"key":"e_1_3_1_15_2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/20014091096738","article-title":"Anthrax toxin","volume":"27","author":"Bhatnagar R","year":"2001","journal-title":"Crit Rev Microbiol"},{"key":"e_1_3_1_16_2","doi-asserted-by":"crossref","first-page":"727","DOI":"10.4049\/jimmunol.96.4.727","article-title":"Immunologic studies of anthrax: IV. Evaluation of the immunogenicity of three components of anthrax toxin","volume":"96","author":"Mahlandt BG","year":"1966","journal-title":"J Immunol"},{"key":"e_1_3_1_17_2","first-page":"387","article-title":"Studies on immunity in anthrax. V. Immunizing activity of alum-precipitated protective antigen","volume":"73","author":"Wright GG","year":"1954","journal-title":"J Immunol"},{"key":"e_1_3_1_18_2","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1128\/IAI.52.2.356-363.1986","article-title":"Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity","volume":"52","author":"Turnbull PCB","year":"1986","journal-title":"Infect Immun"},{"key":"e_1_3_1_19_2","doi-asserted-by":"crossref","first-page":"632","DOI":"10.2105\/AJPH.52.4.632","article-title":"Field evaluation of a human anthrax vaccine","volume":"52","author":"Brachman PS","year":"1962","journal-title":"Am J Public Health"},{"key":"e_1_3_1_20_2","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1016\/S0264-410X(02)00092-0","article-title":"Monitoring anthrax vaccine safety in US military service members on active duty: surveillance of 1998 hospitalizations in temporal association with anthrax immunization","volume":"20","author":"Sato PA","year":"2002","journal-title":"Vaccine"},{"key":"e_1_3_1_21_2","unstructured":"Proceedings of the Workshop on Multinational Cooperation in Development of Mobile Biological and NBC Analytical Laboratories Hradec Kr\u00e1lov\u00e9 Czech Republic Proceedings of the Workshop on Multinational Cooperation in Development of Mobile Biological and NBC Analytical Laboratories R Chlibek BW Threat Reduction\u2013Medical Prophylaxis 2003"},{"key":"e_1_3_1_22_2","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/0264-410X(94)90223-2","article-title":"Human live anthrax vaccine in the former USSR","volume":"12","author":"Slyakhov EN","year":"1994","journal-title":"Vaccine"},{"key":"e_1_3_1_23_2","first-page":"5","article-title":"Anthrax vaccine STI","volume":"1","author":"Ginsburg NN","year":"1946","journal-title":"Collected Works of the Red Army Institute of Epidemiology and Hygiene"},{"key":"e_1_3_1_24_2","first-page":"27","article-title":"Experience in massive aerogenic vaccination of humans against anthrax","volume":"8","author":"Alexandrov NI","year":"1959","journal-title":"Voen Med Zh"},{"key":"e_1_3_1_25_2","first-page":"729","volume-title":"Vaccines","author":"Brachman PS","year":"1994","edition":"2"},{"key":"e_1_3_1_26_2","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/0264-410X(94)90315-8","article-title":"The Vaccine Adverse Event Reporting System (VAERS)","volume":"12","author":"Chen RT","year":"1994","journal-title":"Vaccine"},{"key":"e_1_3_1_27_2","unstructured":"http:\/\/www.promedmail.org ProMED mail website Anthrax Vaccine safety and efficacy . 2002."},{"issue":"3","key":"e_1_3_1_28_2","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/01.jom.0000058345.05741.6b","article-title":"Analysis of adverse events after anthrax immunization in US Army medical personnel","volume":"45","author":"Wasserman GM","year":"2003","journal-title":"J Occup Environ Med"},{"key":"e_1_3_1_29_2","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jama.1997.03540270064028","article-title":"Self-reported illness and health status among Gulf War veterans: a population-based study","volume":"277","author":"Iowa Persian Gulf Study Group","year":"1997","journal-title":"JAMA"},{"key":"e_1_3_1_30_2","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1128\/IAI.70.2.661-664.2002","article-title":"Anthrax spores make an essential contribution to vaccine efficacy","volume":"70","author":"Brossier F","year":"2002","journal-title":"Infect Immun"},{"key":"e_1_3_1_31_2","unstructured":"Brief report on the 4th Anthrax Conference Annapolis USA June 2001 Brief report on the 4th Anthrax Conference H Cuyck"},{"issue":"15","key":"e_1_3_1_32_2","first-page":"13","article-title":"Investigation of Bioterrorism-Related Anthrax and Interim Guidelines for Exposure Management and Antimicrobial Therapy","volume":"49","author":"CDC","year":"2000","journal-title":"MMWR"},{"key":"e_1_3_1_32_3","first-page":"909","volume":"50","year":"2001","journal-title":"MMWR"},{"issue":"45","key":"e_1_3_1_32_4","first-page":"1025","volume":"51","year":"2002","journal-title":"MMWR"},{"key":"e_1_3_1_33_2","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/nbt1001-958","article-title":"Designing a polyvalent inhibitor of anthrax toxin","volume":"19","author":"Mourez M","year":"2001","journal-title":"Nat Biotechnol"},{"key":"e_1_3_1_34_2","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0958-1669(98)80017-7","article-title":"Phage-displayed peptide libraries","volume":"9","author":"Zwick MB","year":"1998","journal-title":"Curr Opin Biotechnol"},{"key":"e_1_3_1_35_2","first-page":"296","article-title":"New anthrax treatment works in rats","volume":"159","author":"Seppa NN","year":"2001","journal-title":"Science News"},{"key":"e_1_3_1_36_2","unstructured":"http:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/ ACIP website Use of Anthrax Vaccine in the United States . 2002."},{"key":"e_1_3_1_37_2","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1016\/S0264-410X(02)00723-5","article-title":"Comprehensive systematic surveillance for adverse effects of anthrax vaccine absorbed, US Armed Forces, 1998\u20132000","volume":"21","author":"Lange JL","year":"2003","journal-title":"Vaccine"},{"key":"e_1_3_1_38_2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0928-8244(03)00085-3","article-title":"Characterisation of the immune response to the UK human anthras vaccine","volume":"36","author":"Baillie L","year":"2003","journal-title":"FEMS Immunol Med Microbiol"},{"key":"e_1_3_1_39_2","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/pds.936","article-title":"Safety of anthrax vaccine: an expanded review and evaluation of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS)","volume":"13","author":"Sever JL","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Annals of Saudi Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.annsaudimed.net\/index.php\/volume-25\/vol25iss2\/948.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T05:35:28Z","timestamp":1693805728000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.annsaudimed.net\/doi\/10.5144\/0256-4947.2005.143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["10.5144\/0256-4947.2005.143"],"URL":"https:\/\/doi.org\/10.5144\/0256-4947.2005.143","relation":{},"ISSN":["0256-4947","0975-4466"],"issn-type":[{"value":"0256-4947","type":"print"},{"value":"0975-4466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,3]]}}}